Abstract:BACKGROUND: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few published data on the clinical impact of this infection or chronic colonisation.METHODS: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the moment of the first positive culture and during the period of colonisation were compared to age (+/-1 year), gender and to Pseudomonas aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.RESULTS: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of our definition of colonisation. Colonised patients had a median age of 20 years (range 11-27 years) and a mean colonisation period of 1.5 (+/-0.9) years. At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11+/-3 versus 16+/-3, p<0.002), lower Brasfield chest X-ray scores (14+/-3 versus 18+/-3, p<0.019), lower FVC values (70%+/-22 versus 94%+/-12, p<0.017) and lower FEV(1) values (55%+/-32 versus 78%+/-23, p=0.123), although the latter did not reach significance. There was no significant difference in body mass index (BMI) (18.7+/-3 kg/m2 versus 19.6+/-3 kg/m2, p=0.8). Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5, p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: -6.25+/-12.34% versus -5.62+/-8.30%, p 0.77, FEV1: -5.62+/-8.30% versus -1.87+/-11.58%, p<0.47).CONCLUSIONS: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older, with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.

Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis

Improved culture detection of Staphylococcus aureus from sputum of patients with cystic fibrosis (CF)

Pulmonary Bacterial Pathogens in Patients with Cystic Fibrosis

Role of viable but non culturable cells in patients with cystic fibrosis in the era of highly effective modulator therapy

Challenges in Laboratory Detection of Fungal Pathogens in the Airways of Cystic Fibrosis Patients

A Polymicrobial Perspective of Pulmonary Infections Exposes an Enigmatic Pathogen in Cystic Fibrosis Patients

Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis

Detection of pathogenic bacteria and biomarkers in lung specimens from cystic fibrosis patients

Microbiology sampling in non-cystic fibrosis bronchiectasis cases from northern Alberta

An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples

Antibiotic treatment of bacterial lung infections in cystic fibrosis

Analysis of the Bacterial Communities Present in Lungs of Patients with Cystic Fibrosis from American and British Centers

Early detection of Pseudomonas aeruginosa – comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF)

Intraspecific Diversity of Populations Isolated from Cystic Fibrosis Respiratory Infections

Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis

Pseudomonas aeruginosa in the Cystic Fibrosis Lung

Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance

The airway microbiome in cystic fibrosis and implications for treatment

Direct Detection of Exophiala and Scedosporium Species in Sputa of Patients with Cystic Fibrosis

Ecological patterns and processes of temporal turnover within lung infection microbiota

Chlamydia pneumoniae and Mycoplasma pneumoniae in children with cystic fibrosis: impact on bacterial respiratory microbiota diversity